Erratum to: “Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the diabetes prevention program” (Metabolism (2016) 65(5) (764–775) (S0026049515003650) (10.1016/j.metabol.2015.11.011));Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program

Metabolism: Clinical and Experimental

Volumn 65, Issue 5, 2016, Pages 764-775

  Goldberg, Ronald B ^a   Temprosa, Marinella ^b   Mele, Lisa ^b   Orchard, Trevor ^c   Mather, Kieren ^d   Bray, George ^e   Horton, Edward ^f,g   Kitabchi, Abbas ^h   Krakoff, Jonathan ⁱ   Marcovina, Santica ^j   Perreault, Leigh ^k   White, Neil ^l  

^a UNIVERSITY OF MIAMI   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d INDIANA UNIVERSITY   (United States)

^e PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^f JOSLIN DIABETES CENTER   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SATURATED FATTY ACID; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; METABOLISM; PARTICLE SIZE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET THERAPY; LIFESTYLE; MIDDLE AGED; MOTOR ACTIVITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVERWEIGHT; PATHOPHYSIOLOGY; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED STATES;

ADIPONECTIN; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COHORT STUDIES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; MOTOR ACTIVITY; OVERWEIGHT; PREDIABETIC STATE; RISK FACTORS; UNITED STATES; WEIGHT LOSS;

EID: 84960441325     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.11.007     Document Type: Erratum

References (31)

1. R.C. Turner, H. Millns, H.A. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, and et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 7134 1998 823 828
2. The Diabetes Prevention Program Research Group Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program Diabetes Care 28 10 2005 2472 2479
3. S.M. Haffner, and M.P. Stern Hazuda Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263 21 1990 2893 2898
4. Diabetes Prevention Program Research Group, W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, and et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 2002 393 403
5. R. Goldberg, M. Temprosa, J. Otvos, J. Brunzell, S. Marcovina, K. Mather, and et al. Lifestyle and metformin treatment favorably influence lipoprotein sub-fraction distribution in the Diabetes Prevention Program J Clin Endocrinol Metab 98 10 2013 3989 3998
6. M. Adiels, S.O. Olofsson, M.R. Taskinen, and J. Borén Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler Thromb Vasc Biol 28 7 2008 1225 1236
7. C.J. Packard Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease Curr Opin Lipidol 17 4 2006 412 417
8. M. Cnop, P.J. Havel, K.M. Utzschneider, D.B. Carr, M.K. Sinha, E.J. Boyko, and et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex Diabetologia 46 4 2003 459 469
9. R. Weiss, J.D. Otvos, A. Flyvbjerg, A.R. Miserez, J. Frystyk, R. Sinnreich, and et al. Adiponectin and lipoprotein particle size Diabetes Care 32 7 2009 1317 1319
10. H. Berrougui, C.N. Momo, and A. Khalil Health benefits of high-density lipoproteins in preventing cardiovascular diseases J Clin Lipidol 6 6 2012 524 533
11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 7 1997 1183 1197
12. E.J. Mayer-Davis, M.Z. Vitolins, S.L. Carmichael, S. Hemphill, G. Tsaroucha, J. Rushing, and et al. Validity and reproducibility of a food frequency interview in a multi-cultural epidemiology Study Ann Epidemiol 9 5 1999 314 324
13. A.M. Kriska, and C.J. Caspersen Introduction to the collection of physical activity questionnaires in a collection of physical activity questionnaires for health-related research A.M. Kriska, C.J. Caspersen, Centers for Disease Control and Prevention Med Sci Sports Exerc 29 1997 S5 S9 [Supp]
14. R.L. Hanson, R.E. Pratley, C. Bogardus, K.M. Narayan, J.M. Roumain, G. Imperatore, and et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies Am J Epidemiol 151 12 2000 190 198
15. J.D. Otvos, E.J. Jeyarajah, D.W. Bennett, and R.M. Krauss Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement Clin Chem 38 9 1992 1632 1638
16. E.J. Jeyarajah, W.C. Cromwell, and J.D. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 4 2006 847 870
17. G.D. Lowe, J. Danesh, S. Lewington, M. Walker, L. Lennon, A. Thomson, and et al. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis Eur Heart J 25 3 2004 252 259
18. D.C. Chan, P.H. Barrett, E.M. Ooi, J. Ji, D.T. Chan, and G.F. Watts Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men J Clin Endocrinol Metab 94 3 2009 989 997
19. F. Matsuura, H. Oku, M. Koseki, J.C. Sandoval, M. Yuasa-Kawase, K. Tsubakio-Yamamoto, and et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver Biochem Biophys Res Commun 358 4 2007 1091 1095
20. J.R. Raiko, M. Oikonen, M. Wendelin-Saarenhovi, N. Siitonen, M. Kähönen, T. Lehtimäki, and et al. Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study Atherosclerosis 224 1 2012 208 212
21. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 8 2004 764 772
22. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219(1-2): 9-15.
23. K. Mather, T. Funahashi, Y. Matsuzawa, S. Edelstein, G. Bray, S. Kahn, and et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program Diabetes 57 4 2008 980 986
24. R. Ganguly, K. Schram, X. Fang, M. Kim, B. Rodrigues, F.S. Thong, and et al. Adiponectin increases LPL activity via RhoA/ROCK-mediated actin remodelling in adult rat cardiomyocytes Endocrinology 152 1 2011 247 254
25. M.R. Taskinen, and E.A. Nikkilä High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man - evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase Clin Chim Acta 112 3 1981 325 332
26. S. Van Linthout, A. Foryst-Ludwig, F. Spillmann, J. Peng, Y. Feng, M. Meloni, and et al. Impact of HDL on adipose tissue metabolism and adiponectin expression Atherosclerosis 210 2 2010 438 444
27. L.M. Belalcazar, W. Lang, S.M. Haffner, R.C. Hoogeveen, F.X. Pi-Sunyer, D.C. Schwenke, and et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study J Lipid Res 53 12 2012 2726 2733
28. Moya M. de la Llera, F.C. McGillicuddy, C.C. Hinkle, M. Byrne, M.R. Joshi, V. Nguyen, and et al. Inflammation modulates human HDL composition and function in vivo Atherosclerosis 222 2 2012 390 394
29. C. Hadigan, J.B. Meigs, J. Rabe, R.B. D'Agostino, P.W. Wilson, I. Lipinska, and et al. Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance J Clin Endocrinol Metab 86 2 2001 939 943
30. American Diabetes Association Position Statement Prevention or Delay of Type 2 Diabetes Diabetes Care 38 Suppl. 1 2015 S31 S32
31. B. Paulweber, P. Valensi, J. Lindström, N.M. Lalic, C.J. Greaves, M. McKee, and et al. A European evidence-based guideline for the prevention of type 2 diabetes Horm Metab Res 42 Suppl. 1 2010 S3 S36